Susana C. Raimondi

St. Jude Children's Research Hospital — United States

Medicine · Health Sciences

92h-index34.3kcitations474works2.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(321), Acute Lymphoblastic Leukemia research(204), Chronic Myeloid Leukemia Treatments(85), Lymphoma Diagnosis and Treatment(43), Hematopoietic Stem Cell Transplantation(43)

Publications474 total

Post-transplant maintenance with sorafenib is safe and effective in pediatric patients with har FLT3/ITD AML: A report from the Children's oncology group protocol AAML1031
Blood·2025
Molecular risk markers define risk of relapse in myeloid leukemia of Down syndrome beyond measurable residual disease
Blood Advances·2025Open Access
Treatment Intensification Does Not Improve Outcome for Children with Myeloid Leukemia of Down Syndrome (ML-DS) Who Are MRD-Positive after Induction Therapy: A Report from the Children's Oncology Group
Blood·2024· 1 cited
Structural variants involving <i>MLLT10</i> fusion are associated with adverse outcomes in pediatric acute myeloid leukemia
Blood Advances·2024· 7 citedOpen Access
Table S6 from Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Disease–Directed Therapy
2023Open Access
Data from Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Disease–Directed Therapy
2023Open Access
Table S6 from Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Disease–Directed Therapy
2023Open Access
Supplementary Data-1 from Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Disease–Directed Therapy
2023Open Access
Data from Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Disease–Directed Therapy
2023Open Access
Tables S1-S5 from Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Disease–Directed Therapy
2023Open Access
Tables S1-S5 from Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Disease–Directed Therapy
2023Open Access
Supplementary Data-1 from Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Disease–Directed Therapy
2023Open Access
Supplementary Figures 1-7 from Malignant Progression of an Ancestral Bone Marrow Clone Harboring a &lt;i&gt;CIC-NUTM2A&lt;/i&gt; Fusion in Isolated Myeloid Sarcoma
2023Open Access
Supplementary Tables 1-5 from Malignant Progression of an Ancestral Bone Marrow Clone Harboring a &lt;i&gt;CIC-NUTM2A&lt;/i&gt; Fusion in Isolated Myeloid Sarcoma
2023Open Access
Data from Malignant Progression of an Ancestral Bone Marrow Clone Harboring a &lt;i&gt;CIC-NUTM2A&lt;/i&gt; Fusion in Isolated Myeloid Sarcoma
2023Open Access
Data from Malignant Progression of an Ancestral Bone Marrow Clone Harboring a &lt;i&gt;CIC-NUTM2A&lt;/i&gt; Fusion in Isolated Myeloid Sarcoma
2023Open Access
Supplementary Figures 1-7 from Malignant Progression of an Ancestral Bone Marrow Clone Harboring a &lt;i&gt;CIC-NUTM2A&lt;/i&gt; Fusion in Isolated Myeloid Sarcoma
2023Open Access
Supplementary Tables 1-5 from Malignant Progression of an Ancestral Bone Marrow Clone Harboring a &lt;i&gt;CIC-NUTM2A&lt;/i&gt; Fusion in Isolated Myeloid Sarcoma
2023Open Access
Data from Functional Properties of &lt;i&gt;KIT&lt;/i&gt; Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia
2023Open Access
Figure S1 from Functional Properties of &lt;i&gt;KIT&lt;/i&gt; Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia
2023Open Access
page 1 of 24Next →

Frequent Co-authors

Ching‐Hon Pui(25), James R. Downing(24), Jeffrey E. Rubnitz(16), Sheila Shurtleff(15), William E. Evans(13), Raul C. Ribeiro(13), Dario Campana(12), Jinghui Zhang(11), Charles G. Mullighan(11), Cheng Cheng(10), Elaine Coustan‐Smith(10), Frederick G. Behm(10), Deqing Pei(9), Mary V. Relling(8), Stanley Pounds(8), Guangchun Song(8), Gang Wu(7), John Easton(7), Michael Rusch(7), Stephen P. Hunger(7)